Clinical trials: Lymphoma, Hodgkins
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) and to see how well they work in treating patients with diffuse large B-cell…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma
- Trial name
- NCT02628405
- Testing
- Carboplatin, Etoposide, Ifosfamide
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Academic and Community Cancer Research United
Lymphoma, Non-Hodgkin
Assessment of Treatment Response Using PET/CT Scanner - Non Hodgkin's Lymphoma
In this study the treatment process will be closely monitored using a novel imaging technology, a PET/CT scanner. PET stands for Positron Emission Tomography and in this case it will be combined with a conventional x-ray…
- Trial name
- NCT00188929
- Testing
- PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia
The clonoSEQ® Watch Registry
This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL).
- Conditions
- Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma
- Trial name
- NCT04545333
- Testing
- clonoSEQ Assay
- Where
- 14 sites in United States
- Volunteers
- 465 people
- Sponsor
- Adaptive Biotechnologies
Hodgkin's Lymphoma
A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma
This study is a multi-center, non-randomized, single-arm, open clinical trial.
- Trial name
- NCT04665063
- Testing
- Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Non-Hodgkin's Lymphoma
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma
The purpose of this study is to provide data on the safety and efficacy of pegfilgrastim when administered on the same day versus the next day of chemotherapy, as measured by the duration of grade 4 neutropenia.
- Trial name
- NCT00115193
- Testing
- pegfilgrastim
- Volunteers
- 77 people
- Sponsor
- Amgen
Lymphoma
Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of cancer cells.
- Trial name
- NCT00003152
- Testing
- filgrastim, recombinant interferon alfa, cyclophosphamide
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 469 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-Hodgkin's Lymphoma
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement
The purpose of this study is to determine the proper dose, effectiveness, and safety of using Iodine-131 Anti-B1 Antibody for the treatment of patients with previously treated non-Hodgkin's lymphoma (NHL) who have greater than…
- Trial name
- NCT00022906
- Testing
- Iodine-131 Anti-B1 Antibody
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Corixa Corporation
Lymphoma, B-Cell, CAR-T
C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma
It is a single-arm, open-label clinical study to assess the safety and efficacy of the C752 CAR-T Cells for patients with CD19+ refractory/relapsed B cell non-Hodgkin lymphoma.
- Trial name
- NCT06210243
- Testing
- C752
- Where
- China
- Volunteers
- 2 people
- Sponsor
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Non-Hodgkin's Lymphoma
MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma.
This single arm study will evaluate the safety and efficacy of MabThera maintenance therapy following a MabThera-containing induction regimen in first line or relapsed patients with follicular non-Hodgkin's lymphoma.
- Trial name
- NCT00430352
- Testing
- rituximab [MabThera/Rituxan]
- Where
- 178 sites in Albania, Argentina and 22 more
- Volunteers
- 545 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma
This research study is assessing the feasibility of reduced intensity allogeneic hematopoietic stem cell transplantation (HSCT) as a possible treatment for relapsed / refractory non-Hodgkin lymphoma involving the central nervous…
- Trial name
- NCT02724904
- Testing
- Allogeneic stem cell transplantation, Fludarabine, Thiotepa
- Where
- 2 sites in United States
- Sponsor
- Massachusetts General Hospital
Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma
Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma
This international multi-center, randomized, controlled, open-label study investigated the pharmacokinetics, pharmacodynamics, efficacy and safety of BCD-020 (INN: rituximab, CJSC Biocad) versus MabThera® (INN: rituximab, F.
- Conditions
- Follicular Non-Hodgkin's Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
- Trial name
- NCT01701232
- Testing
- rituximab
- Where
- 62 sites in Colombia, India and 3 more
- Volunteers
- 174 people
- Sponsor
- Biocad
Lymphoma
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
RATIONALE: Giving high-dose chemotherapy drugs, such as carmustine, etoposide, and cyclophosphamide, before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00641381
- Testing
- carmustine, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Non-hodgkin's Lymphoma
Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma
To evaluate the safety and efficacy of SL19+22 in patients with relapsed or refractory non-Hodgkin's lymphoma.
- Trial name
- NCT05206071
- Testing
- CD19+22 CAR-T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Breast Cancer, Lymphoma
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Filgrastim and stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's…
- Trial name
- NCT00005993
- Testing
- aldesleukin, filgrastim, recombinant human stem cell factor
- Sponsor
- Masonic Cancer Center, University of Minnesota
Kidney Cancer, Leukemia
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who…
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00066599
- Testing
- voriconazole
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia,B-Cell, Non-hodgkin Lymphoma,B Cell
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
- Trial name
- NCT06346912
- Testing
- CD19-BAFF Targeted CAR T-cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Non-Hodgkin's Lymphoma
An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma
This prospective observational study will evaluate the safety and efficacy of first-line rituximab maintenance therapy in participants with follicular non-Hodgkin's lymphoma.
- Trial name
- NCT01684865
- Testing
- Rituximab
- Where
- North Macedonia
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Lymphoma
S8516-S8736-S9125-S9240 Research Study of Genes in Tissue Samples From Patients With B-cell Non-Hodgkin Lymphoma
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00985699
- Testing
- polymorphism analysis, laboratory biomarker analysis, pharmacogenomic studies
- Volunteers
- 337 people
- Sponsor
- SWOG Cancer Research Network
Non-Hodgkin's Lymphoma
Ph II CHOP+Velcade in Mediastinal LBCL
The main purpose of this study is to begin to collect information and try to learn whether or not VELCADE, when added to standard chemotherapy with CHOP/Rituxan, works in treating patients mediastinal large B-cell lymphoma.
- Trial name
- NCT00361621
- Testing
- bortezomib, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Dana-Farber Cancer Institute
Hodgkin's Lymphoma, Leukemia
Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation
The goal of this project is to refine and evaluate the feasibility of a brief, behavioral intervention to improve the recovery following hematopoietic stem cell transplantation (HSCT).
- Conditions
- Hodgkin's Lymphoma, Leukemia, Lymphoid Leukemia, Multiple Myeloma
- Trial name
- NCT02719821
- Testing
- Behavioral techniques
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Wisconsin, Madison
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.